1921
Volume 102, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Although there has been an increasing incidence of bacteremia caused by extended-spectrum beta-lactamase (ESBL)–producing Enterobacteriaceae (ESBL-E) across South East Asia, there are sparse data from the Lao PDR, where laboratory capacity for antimicrobial resistance surveillance is limited. We, therefore, retrospectively reviewed bacteremia caused by ESBL-producing and between 2010 and 2014 at Mahosot Hospital, Vientiane, Lao PDR. Clinical and laboratory data relating to all episodes of ESBL-E bacteremia were reviewed over the 5-year period and compared with non–ESBL-E bacteremia. Blood cultures positive for or were identified retrospectively from laboratory records. Clinical and laboratory data were extracted from research databases and case notes and analyzed using STATA. Between 2010 and 2014, we identified 360 patients with ( = 249) or ( = 111) bacteremia, representing 34.8% of all patients with clinically significant bacteremia Seventy-two (20%) isolates produced ESBL; accounted for 15.3% (55/360) and for 4.7% (17/360), respectively. The incidence of ESBL-producing bacteremia rose during the study period. By multiple logistic analysis, reported antibiotic use in the previous week was significantly associated with ESBL positivity ( < 0.001, odds ratio 3.89). Although multiresistant, most ESBL-producing and remained susceptible to meropenem (65/65; 100%) and amikacin (64/65; 98.5%). We demonstrated an alarming increase in the incidence of ESBL-E as a cause of bacteremia in Vientiane during the study period. This has implications for empiric therapy of sepsis in Laos, and ongoing surveillance is essential.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0304
2020-03-09
2020-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/5/tpmd190304.html?itemId=/content/journals/10.4269/ajtmh.19-0304&mimeType=html&fmt=ahah

References

  1. Laupland KB, Church DL, 2014. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 27: 647664.
    [Google Scholar]
  2. Laupland KB, 2013. Incidence of bloodstream infection: a review of population-based studies. Clin Microbiol Infect 19: 492500.
    [Google Scholar]
  3. de Kraker ME, Davey PG, Grundmann H, 2011. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 8: e1001104.
    [Google Scholar]
  4. Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, Hinjoy S, Day NP, Peacock SJ, Limmathurotsakul D, 2016. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife 5: e18082.
    [Google Scholar]
  5. Paterson DL, 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 34 (Suppl 1): S20S28.
    [Google Scholar]
  6. Tacconelli E et al., 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18: 318327.
    [Google Scholar]
  7. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL, 2009. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the study for monitoring antimicrobial resistance trends (SMART) program, 2007. Antimicrob Agents Chemother 53: 32803284.
    [Google Scholar]
  8. Suwantarat N, Carroll KC, 2016. Epidemiology and molecular characterization of multidrug-resistant gram-negative bacteria in southeast Asia. Antimicrob Resist Infect Control 5: 15.
    [Google Scholar]
  9. Kiratisin P, Chongthaleong A, Tan TY, Lagamayo E, Roberts S, Garcia J, Davies T, 2012. Comparative in vitro activity of carbapenems against major gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents 39: 311316.
    [Google Scholar]
  10. Phetsouvanh R et al., 2006. Causes of community-acquired bacteremia and patterns of antimicrobial resistance in Vientiane, Laos. Am J Trop Med Hyg 75: 978985.
    [Google Scholar]
  11. Stoesser N, Crook DW, Moore CE, Phetsouvanh R, Chansamouth V, Newton PN, Jones N, 2012. Characteristics of CTX-M ESBL-producing Escherichia coli isolates from the Lao People’s Democratic Republic, 2004–09. J Antimicrob Chemother 67: 240242.
    [Google Scholar]
  12. Stoesser N et al., 2015. Colonization with Enterobacteriaceae producing ESBLs in children attending pre-school childcare facilities in the Lao People’s Democratic Republic. J Antimicrob Chemother 70: 18931897.
    [Google Scholar]
  13. CLSI, 2014. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement. CLSI Document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute.
    [Google Scholar]
  14. Scheuerman O et al., 2018. Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 39: 660667.
    [Google Scholar]
  15. Romero L, Lopez L, Rodriguez-Bano J, Ramon Hernandez J, Martinez-Martinez L, Pascual A, 2005. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases. Clin Microbiol Infect 11: 625631.
    [Google Scholar]
  16. Sakellariou C, Gürntke S, Steinmetz I, Kohler C, Pfeifer Y, Gastmeier P, Schwab F, Kola A, Deja M, Leistner R, 2016. Sepsis caused by extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: comparison of severity of sepsis, delay of anti-infective therapy and ESBL genotype. PLoS One 11: e0158039.
    [Google Scholar]
  17. Kanoksil M, Jatapai A, Peacock SJ, Limmathurotsakul D, 2013. Epidemiology, microbiology and mortality associated with community-acquired bacteremia in northeast Thailand: a multicenter surveillance study. PLoS One 8: e54714.
    [Google Scholar]
  18. Vlieghe ER, Phe T, De Smet B, Veng HC, Kham C, Lim K, Koole O, Lynen L, Peetermans WE, Jacobs JA, 2013. Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns. PLoS One 8: e59775.
    [Google Scholar]
  19. Dat VQ et al., 2017. Bacterial bloodstream infections in a tertiary infectious diseases hospital in northern Vietnam: aetiology, drug resistance, and treatment outcome. BMC Infect Dis 17: 493.
    [Google Scholar]
  20. Myat TO, Hannaway RF, Zin KN, Htike WW, Win KK, Crump JA, Murdoch DR, Ussher JE, 2017. ESBL- and carbapenemase-producing Enterobacteriaceae in patients with bacteremia, Yangon, Myanmar, 2014. Emerg Infect Dis 23: 857859.
    [Google Scholar]
  21. Quan J, Zhao D, Liu L, Chen Y, Zhou J, Jiang Y, Du X, Zhou Z, Akova M, Yu Y, 2017. High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China. J Antimicrob Chemother 72: 273280.
    [Google Scholar]
  22. Wu U-I, Yang C-S, Chen W-C, Chen Y-C, Chang S-C, 2010. Risk factors for bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. J Microbiol Immunol Infect 43: 310316.
    [Google Scholar]
  23. Khrongwong M, Chatgaew C, Chaita S, 2011. Risk factors of extended-spectrum beta-lactamase producing Enterobacteriaceae bacteremia in Thai emergency department: a retrospective case-control study. Asian Biomed 5: 129138.
    [Google Scholar]
  24. Kim SH et al., 2013. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann Hematol 92: 533541.
    [Google Scholar]
  25. Kumar M, Dutta R, Saxena S, Singhal S, 2015. Risk factor analysis in clinical isolates of ESBL and MBL (including NDM-1) producing Escherichia coli and Klebsiella species in a tertiary care hospital. J Clin Diagn Res 9: DC08DC13.
    [Google Scholar]
  26. Nakai H, Hagihara M, Kato H, Hirai J, Nishiyama N, Koizumi Y, Sakanashi D, Suematsu H, Yamagishi Y, Mikamo H, 2016. Prevalence and risk factors of infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. J Infect Chemother 22: 319326.
    [Google Scholar]
  27. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO, 2001. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32: 11621171.
    [Google Scholar]
  28. Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, Xie X, 2002. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 28: 17181723.
    [Google Scholar]
  29. Martinez JA, Aguilar J, Almela M, Marco F, Soriano A, Lopez F, Balasso V, Pozo L, Mensa J, 2006. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 58: 10821085.
    [Google Scholar]
  30. Chen YH, Yao WZ, Wu R, Zhou QT, Liu ZY, Zhang XW, 2008. Risk factors and prognosis in 31 patients with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection. Zhonghua Jie He He Hu Xi Za Zhi 31: 815819.
    [Google Scholar]
  31. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Gálvez J, Perea EJ, Pascual A, 2008. Risk-factors for emerging bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect 14: 180183.
    [Google Scholar]
  32. Razazi K, Derde LPG, Verachten M, Legrand P, Lesprit P, Brun-Buisson C, 2012. Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38: 17691778.
    [Google Scholar]
  33. Ferrández Quirante O, Grau Cerrato S, Luque Pardos S, 2011. Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Braz J Infect Dis 15: 370376.
    [Google Scholar]
  34. Quet F et al., 2015. Antibiotic prescription behaviours in Lao People’s Democratic Republic: a knowledge, attitude and practice survey. Bull World Health Org 93: 219227.
    [Google Scholar]
  35. Falcone M et al., 2014. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae. Ann Ig 26: 293304.
    [Google Scholar]
  36. Chopra T et al., 2015. Risk factors for bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: a focus on antimicrobials including cefepime. Am J Infect Control 43: 719723.
    [Google Scholar]
  37. Superti SV, Augusti G, Zavascki AP, 2009. Risk factors for and mortality of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Rev Inst Med Trop São Paulo 51: 211216.
    [Google Scholar]
  38. Rottier WC, Ammerlaan HS, Bonten MJ, 2012. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 67: 13111320.
    [Google Scholar]
  39. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y, 2006. Clinical and economic impact of bacteremia with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 50: 12571262.
    [Google Scholar]
  40. Tumbarello M et al., 2007. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51: 19871994.
    [Google Scholar]
  41. Vlieghe ER, Huang TD, Phe T, Bogaerts P, Berhin C, De Smet B, Peetermans WE, Jacobs JA, Glupczynski Y, 2015. Prevalence and distribution of beta-lactamase coding genes in third-generation cephalosporin-resistant Enterobacteriaceae from bloodstream infections in Cambodia. Eur J Clin Microbiol Infect Dis 34: 12231229.
    [Google Scholar]
  42. Noguchi T, Matsumura Y, Yamamoto M, Nagao M, Takakura S, Ichiyama S, 2017. Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study. BMC Infect Dis 17: 44.
    [Google Scholar]
  43. Sangare SA et al., 2016. Prevalence of ESBL-producing Enterobacteriaceae isolated from blood cultures in Mali. J Infect Dev Ctries 10: 10591064.
    [Google Scholar]
  44. 2013. Mahosost Microbiology Review 7: 15.
  45. Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A, 2011. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother 66: 13831391.
    [Google Scholar]
  46. Netikul T, Kiratisin P, 2015. Genetic characterization of carbapenem-resistant Enterobacteriaceae and the spread of carbapenem-resistant Klebsiella pneumoniae ST340 at a university hospital in Thailand. PLoS One 10: e0139116.
    [Google Scholar]
  47. Munoz-Price LS et al., 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13: 785796.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0304
Loading
/content/journals/10.4269/ajtmh.19-0304
Loading

Data & Media loading...

  • Received : 21 Apr 2019
  • Accepted : 26 Jan 2020
  • Published online : 09 Mar 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error